Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUX-Lung 6: Afatinib vs Chemotherapy in EGFR-mutant NSCLC
NCT01121393Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2010
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of afatinib in lung adenocarcinoma (LUAD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Progression-free Survival up to 168 weeks. Started Apr 2010; status: completed.
02
Drugs
afatinib
03
Conditions
lung adenocarcinoma (LUAD)
Beyond the preview
Go deeper on NCT01121393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01121393.